# CCC Intelligent Solutions Holdings Inc.: financial statements, quarterly

CCC · Nasdaq · CIK 1818201 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ccc.md) · [Financials](/companies/ccc/financials.md) · [Filings](/companies/ccc/filings.md) · [Insiders](/companies/ccc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ccc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [229 d](/filings/0001193125-26-067448.md) | [227](/filings/0000950170-25-063985.md) | [233](/filings/0000950170-25-101006.md) | [238](/filings/0001193125-25-257514.md) | [246 d](/filings/0001193125-26-067448.md) | [252](/filings/0000950170-25-063985.md) | [260](/filings/0001193125-26-324993.md) | [267](/filings/0001193125-26-437061.md) | [278 d](/filings/0001193125-26-067448.md) | not reported | [286](/filings/0001193125-26-324993.md) | [294](/filings/0001193125-26-437061.md) |
| Cost of revenue | $m | [55.9 d](/filings/0001193125-26-067448.md) | [59.4](/filings/0000950170-25-063985.md) | [55.3](/filings/0000950170-25-101006.md) | [55.1](/filings/0001193125-25-257514.md) | [61.2 d](/filings/0001193125-26-067448.md) | [66.6](/filings/0000950170-25-063985.md) | [66.4](/filings/0001193125-26-324993.md) | [74.1](/filings/0001193125-26-437061.md) | [73.0 d](/filings/0001193125-26-067448.md) | not reported | [75.3](/filings/0001193125-26-324993.md) | [76.1](/filings/0001193125-26-437061.md) |
| Gross profit | $m | [173 d](/filings/0001193125-26-067448.md) | [168](/filings/0000950170-25-063985.md) | [177](/filings/0000950170-25-101006.md) | [183](/filings/0001193125-25-257514.md) | [185 d](/filings/0001193125-26-067448.md) | [185](/filings/0000950170-25-063985.md) | [194](/filings/0001193125-26-324993.md) | [193](/filings/0001193125-26-437061.md) | [205 d](/filings/0001193125-26-067448.md) | not reported | [211](/filings/0001193125-26-324993.md) | [218](/filings/0001193125-26-437061.md) |
| Research and development | $m | [45.2 d](/filings/0001193125-26-067448.md) | [49.5](/filings/0000950170-25-063985.md) | [49.3](/filings/0000950170-25-101006.md) | [49.5](/filings/0001193125-25-257514.md) | [53.2 d](/filings/0001193125-26-067448.md) | [61.8](/filings/0000950170-25-063985.md) | [59.9](/filings/0001193125-26-324993.md) | [52.9](/filings/0001193125-26-437061.md) | [52.9 d](/filings/0001193125-26-067448.md) | not reported | [53.0](/filings/0001193125-26-324993.md) | [53.0](/filings/0001193125-26-437061.md) |
| Operating income | $m | [19.4 d](/filings/0001193125-26-067448.md) | [7.8](/filings/0000950170-25-063985.md) | [22.5](/filings/0000950170-25-101006.md) | [28.7](/filings/0001193125-25-257514.md) | [21.1 d](/filings/0001193125-26-067448.md) | [(10.7)](/filings/0000950170-25-063985.md) | [24.5](/filings/0001193125-26-324993.md) | [30.0](/filings/0001193125-26-437061.md) | [50.1 d](/filings/0001193125-26-067448.md) | not reported | [47.6](/filings/0001193125-26-324993.md) | [57.4](/filings/0001193125-26-437061.md) |
| Interest expense | $m | [21.1 d](/filings/0001193125-26-067448.md) | [16.5](/filings/0000950170-25-063985.md) | [16.6](/filings/0000950170-25-101006.md) | [16.4](/filings/0001193125-25-257514.md) | [15.2 d](/filings/0001193125-26-067448.md) | [16.9](/filings/0000950170-25-063985.md) | [17.8](/filings/0001193125-26-324993.md) | [18.1](/filings/0001193125-26-437061.md) | [18.1 d](/filings/0001193125-26-067448.md) | not reported | [20.4](/filings/0001193125-26-324993.md) | [20.9](/filings/0001193125-26-437061.md) |
| Income tax | $m | [6.8 d](/filings/0001193125-26-067448.md) | [(4.2)](/filings/0000950170-25-063985.md) | [4.3](/filings/0000950170-25-101006.md) | [8.9](/filings/0001193125-25-257514.md) | [4.1 d](/filings/0001193125-26-067448.md) | [(13.4)](/filings/0000950170-25-063985.md) | [(7.2)](/filings/0001193125-26-324993.md) | [15.4](/filings/0001193125-26-437061.md) | [25.0 d](/filings/0001193125-26-067448.md) | not reported | [9.8](/filings/0001193125-26-324993.md) | [9.7](/filings/0001193125-26-437061.md) |
| Net income | $m | [26.3 d](/filings/0001193125-26-067448.md) | [(0.6)](/filings/0000950170-25-063985.md) | [21.4](/filings/0000950170-25-101006.md) | [4.1](/filings/0001193125-25-257514.md) | [6.3 d](/filings/0001193125-26-067448.md) | [(17.4)](/filings/0000950170-25-063985.md) | [13.0](/filings/0001193125-26-324993.md) | [(2.0)](/filings/0001193125-26-437061.md) | [8.1 d](/filings/0001193125-26-067448.md) | [15.4](/filings/0001193125-26-437061.md) | [20.8](/filings/0001193125-26-324993.md) | [30.2](/filings/0001193125-26-437061.md) |
| Diluted EPS | $ per share | not reported | [0.00](/filings/0000950170-25-063985.md) | [0.03](/filings/0000950170-25-101006.md) | [0.00](/filings/0001193125-25-257514.md) | not reported | [(0.03)](/filings/0000950170-25-063985.md) | [0.02](/filings/0001193125-26-324993.md) | [0.00](/filings/0001193125-26-437061.md) | not reported | not reported | [0.04](/filings/0001193125-26-324993.md) | [0.05](/filings/0001193125-26-437061.md) |
| Basic EPS | $ per share | not reported | [0.00](/filings/0000950170-25-063985.md) | [0.03](/filings/0000950170-25-101006.md) | [0.00](/filings/0001193125-25-257514.md) | not reported | [(0.03)](/filings/0000950170-25-063985.md) | [0.02](/filings/0001193125-26-324993.md) | [0.00](/filings/0001193125-26-437061.md) | not reported | not reported | [0.04](/filings/0001193125-26-324993.md) | [0.05](/filings/0001193125-26-437061.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [196](/filings/0000950170-25-026848.md) | [191](/filings/0000950170-24-050638.md) | [238](/filings/0000950170-24-088015.md) | [286](/filings/0000950170-24-117787.md) | [399](/filings/0001193125-26-067448.md) | [130](/filings/0000950170-25-063985.md) | [55.1](/filings/0000950170-25-101006.md) | [97.1](/filings/0001193125-25-257514.md) | [111](/filings/0001193125-26-437061.md) | not reported | [116](/filings/0001193125-26-324993.md) | [203](/filings/0001193125-26-437061.md) |
| Current assets | $m | [350](/filings/0000950170-25-026848.md) | [343](/filings/0000950170-24-050638.md) | [409](/filings/0000950170-24-088015.md) | [468](/filings/0000950170-24-117787.md) | [565](/filings/0001193125-26-067448.md) | [298](/filings/0000950170-25-063985.md) | [278](/filings/0000950170-25-101006.md) | [331](/filings/0001193125-25-257514.md) | [335](/filings/0001193125-26-437061.md) | not reported | [331](/filings/0001193125-26-324993.md) | [427](/filings/0001193125-26-437061.md) |
| Total assets | $m | [3,051](/filings/0000950170-25-026848.md) | [3,024](/filings/0000950170-24-050638.md) | [3,079](/filings/0000950170-24-088015.md) | [3,115](/filings/0000950170-24-117787.md) | [3,183](/filings/0001193125-26-067448.md) | [3,612](/filings/0000950170-25-063985.md) | [3,565](/filings/0000950170-25-101006.md) | [3,592](/filings/0001193125-25-257514.md) | [3,573](/filings/0001193125-26-437061.md) | not reported | [3,532](/filings/0001193125-26-324993.md) | [3,602](/filings/0001193125-26-437061.md) |
| Current liabilities | $m | [153](/filings/0000950170-25-026848.md) | [136](/filings/0000950170-24-050638.md) | [147](/filings/0000950170-24-088015.md) | [147](/filings/0000950170-24-117787.md) | [155](/filings/0001193125-26-067448.md) | [194](/filings/0000950170-25-063985.md) | [201](/filings/0000950170-25-101006.md) | [218](/filings/0001193125-25-257514.md) | [234](/filings/0001193125-26-437061.md) | not reported | [212](/filings/0001193125-26-324993.md) | [208](/filings/0001193125-26-437061.md) |
| Total liabilities | $m | [1,252](/filings/0000950170-25-026848.md) | [1,222](/filings/0000950170-24-050638.md) | [1,167](/filings/0000950170-24-088015.md) | [1,154](/filings/0000950170-24-117787.md) | [1,164](/filings/0001193125-26-067448.md) | [1,434](/filings/0000950170-25-063985.md) | [1,429](/filings/0000950170-25-101006.md) | [1,462](/filings/0001193125-25-257514.md) | [1,786](/filings/0001193125-26-437061.md) | not reported | [1,759](/filings/0001193125-26-324993.md) | [1,760](/filings/0001193125-26-437061.md) |
| Long-term debt | $m | [768](/filings/0000950170-25-026848.md) | [766](/filings/0000950170-24-050638.md) | [764](/filings/0000950170-24-088015.md) | [763](/filings/0000950170-24-117787.md) | [761](/filings/0001193125-26-067448.md) | [975](/filings/0000950170-25-063985.md) | [973](/filings/0000950170-25-101006.md) | [971](/filings/0001193125-25-257514.md) | [1,265](/filings/0001193125-26-437061.md) | not reported | [1,259](/filings/0001193125-26-324993.md) | [1,257](/filings/0001193125-26-437061.md) |
| Current portion of debt | $m | [8.0](/filings/0000950170-25-026848.md) | [8.0](/filings/0000950170-24-050638.md) | [8.0](/filings/0000950170-24-088015.md) | [8.0](/filings/0000950170-24-117787.md) | [8.0](/filings/0001193125-26-067448.md) | [10.0](/filings/0000950170-25-063985.md) | [10.0](/filings/0000950170-25-101006.md) | [10.0](/filings/0001193125-25-257514.md) | [13.0](/filings/0001193125-26-437061.md) | not reported | [13.0](/filings/0001193125-26-324993.md) | [13.0](/filings/0001193125-26-437061.md) |
| Shareholders' equity | $m | [1,782](/filings/0001193125-26-067448.md) | [1,784](/filings/0001193125-25-257514.md) | [1,894](/filings/0001193125-25-257514.md) | [1,940](/filings/0001193125-25-257514.md) | [1,998](/filings/0001193125-26-437061.md) | [2,177](/filings/0001193125-26-437061.md) | [2,136](/filings/0001193125-26-437061.md) | [2,130](/filings/0001193125-26-437061.md) | [1,787](/filings/0001193125-26-437061.md) | [1,721](/filings/0001193125-26-437061.md) | [1,773](/filings/0001193125-26-437061.md) | [1,842](/filings/0001193125-26-437061.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [69.6 d](/filings/0000950170-24-088015.md) | [60.5 d](/filings/0000950170-24-117787.md) | [86.9 d](/filings/0001193125-26-067448.md) | [55.2](/filings/0000950170-25-063985.md) | [51.8 d](/filings/0000950170-25-101006.md) | [63.2 d](/filings/0001193125-25-257514.md) | [114 d](/filings/0001193125-26-067448.md) | [58.5](/filings/0000950170-25-063985.md) | [43.1 d](/filings/0001193125-26-324993.md) | [94.8 d](/filings/0001193125-26-437061.md) | [119 d](/filings/0001193125-26-067448.md) | [100 d](/filings/0001193125-26-437061.md) |
| Capital expenditure | $m | [14.6 d](/filings/0000950170-24-088015.md) | [14.1 d](/filings/0000950170-24-117787.md) | [11.8 d](/filings/0001193125-26-067448.md) | [15.7](/filings/0000950170-25-063985.md) | [15.6 d](/filings/0000950170-25-101006.md) | [13.8 d](/filings/0001193125-25-257514.md) | [7.9 d](/filings/0001193125-26-067448.md) | [14.8](/filings/0000950170-25-063985.md) | [15.7 d](/filings/0001193125-26-324993.md) | [16.1 d](/filings/0001193125-26-437061.md) | [14.3 d](/filings/0001193125-26-067448.md) | [18.0 d](/filings/0001193125-26-437061.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | [0.0](/filings/0000950170-25-063985.md) | [0.0 d](/filings/0000950170-25-101006.md) | [0.0 d](/filings/0001193125-25-257514.md) | [0.0 d](/filings/0001193125-26-067448.md) | [72.3](/filings/0000950170-25-063985.md) | [100 d](/filings/0001193125-26-324993.md) | [40.0 d](/filings/0001193125-26-437061.md) | [388 d](/filings/0001193125-26-067448.md) | [0.0 d](/filings/0001193125-26-437061.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [644](/filings/0000950170-23-059524.md) | [646](/filings/0000950170-24-050638.md) | [621](/filings/0000950170-24-088015.md) | [625](/filings/0000950170-24-117787.md) | [598](/filings/0000950170-25-063985.md) | [638](/filings/0000950170-25-101006.md) | [642](/filings/0001193125-25-257514.md) | [637](/filings/0000950170-25-063985.md) | [661](/filings/0001193125-26-324993.md) | [631](/filings/0001193125-26-437061.md) | [585](/filings/0001193125-26-324993.md) | [593](/filings/0001193125-26-437061.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 591,041,172 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0001193125-26-437061.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 08:23 ET. No prices; not investment advice.